Abraxane nab-paclitaxel: Phase III data

The open-label, international Phase III MPACT trial in 861 treatment-naïve patients with metastatic pancreatic cancer showed that 125 mg/m 2 Abraxane plus gemcitabine met the primary endpoint of OS vs. gemcitabine alone. Celgene said the data have been submitted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco in January. Based on the data, Celgene plans to submit regulatory applications in the U.S., EU and other markets for Abraxane to treat metastatic pancreatic cancer with an sNDA submission to FDA planned for 2013. ...